NOV 25, 2018 07:26 PM PST

Advancing Drug Therapies for an Increasing Case of a Parasitic infection Among Displaced Syrians

WRITTEN BY: Nouran Amin

Cases of Cutaneous leishmaniasis (CL), a parasitic disease, has increased dramatically in Syria and neighboring countries as a result of the conflict-related displacement of Syrians.

Drawing depicting family feeling war-torn Syria.

Credit: Jan Birck via Public International Radio (PRI.org)

Now, a recent study published in PLOS Neglected Tropical Diseases by Rana El Hajj at the American University of Beirut, Lebanon describes the development of a novel immunomodulatory analog that will seek to advance the treatment of CL.

Cutaneous leishmaniasis (CL) is a parasitic infection with occurrences throughout the Americas from Texas to Argentina, and in the Old World, particularly the Middle East and North Africa. The infection is spread via by a female sandfly and is diagnosed annually in travelers, immigrants, and military personnel. Health care providers in the United States must alert to the diagnosis of leishmaniasis in travelers flying from endemic areas.

Presently, current therapeutics for CL can induce partial or complete cure. But these therapies come with multiple limitations, such as repetitive painful administrations, lack of availability, increased cost, and the emergence of resistant strains. Most importantly, the efficacy of these therapies are effected by the patient's age and immune system.

Learn more about Cutaneous leishmaniasis (CL):

In the study, the pre-clinical efficacy of the immunomodulatory drug--Imiquimod and one of its analogs, EAPB0503--on two strains (Leishmania major and Leishmania tropica) were investigated. These strains are known to cause CL in regions of the Middle East. These drugs were also tested on freshly isolated parasites from biopsies that proved their leishmanicidal potency.

The authors note, "Our findings establish Imiquimod as a strong candidate for treating L. tropica and show the higher potency of its analog EAPB0503 against CL."

The study is a promising solution to a current global health crisis and will effectively combat the increasing cases of CL.

Source: American Family Physician, PLOS Neglected Tropical Diseases

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
OCT 13, 2019
Health & Medicine
OCT 13, 2019
FDA Approves New Treatment for Extensively Drug-Resistant TB
Last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for a severe form of multi-drug-resistant tuberculosis of the lungs. Accord...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Triple Drug Combo Extends Fruit Fly Lifespan
A study published in the Proceedings of the National Academy of Sciences (PNAS) suggests that a triple drug combination can extend the lifespan of a fruit ...
Loading Comments...